A.Vennegoor, MS Center Amsterdam, MS Center Amsterdam, the NetherlandsA.Vennegoor@vumc.nl
M.P. Wattjes, E.T.L. van Munster, J. Killestein, and C.H.
Submitted May 25, 2011
We thank Ko et al. for their interest in our article and sharing their experience with PML in a natalizumab-treated relapsing-remitting MS patient.
Their case underlines that the course of PML can be clinically and radiologically protracted despite continuing natalizumab treatment. It confirms our message that clinical and radiological vigilance is vital.
Disclosures: See original article for full disclosure list.
We thank Ko et al. for their interest in our article and sharing their experience with PML in a natalizumab-treated relapsing-remitting MS patient.
Their case underlines that the course of PML can be clinically and radiologically protracted despite continuing natalizumab treatment. It confirms our message that clinical and radiological vigilance is vital.
Disclosures: See original article for full disclosure list.